ClinicalTrials.gg
CompletedNCT05845398Updated Jan 14, 2026Results posted

Phase 1b Study of DCR-AUD in Healthy Volunteers

A Phase 1 interventional study of DCR-AUD and Placebo in Alcohol Use Disorder, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (part of Novo Nordisk A/S) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,076 studies in Alcoholism with a site in United States — 190 open to participants now, 230 under way, 16 of them phase 3. Alcoholism · United States.

Enrollment
860th of 992
16 · median 80
Started
2023
with 52 others
Phase 1
103 of 1,076
23 open now
Registered
887th of 1,076
by date

Among the 1,076 studies in Alcoholism with a site in United States, this one is the 860th largest by enrollment of the 992 interventional ones that give a count, is one of 53 that started in 2023, is one of 103 in phase 1, and was the 887th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

190 of the 1,076 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,076 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of of repeat doses of DCR-AUD in adult healthy volunteers who are social drinkers.

The main questions it aims to answer are:

  • Are repeat doses of DCR-AUD safe and well-tolerated in healthy adults who are social drinkers?
  • How does the drug behave inside the human body and how it is removed from the human body?
  • What are the symptoms the drug may cause with alcohol consumption?

Participants will:

  • Receive multiple doses of DCR-AUD.
  • Have assessment visits through Week 24.
  • Participate in up to 10 Ethanol Interaction Assessments (EIAs) to see how the body is affected by DCR-AUD.

Researchers will compare the groups of participates who receive study drug with the group of participants who receive placebo to see if the study drug is safe and tolerable and whether the study drug has any real effect.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 21 to 65 years, inclusive, at the time of signing .
  2. Overtly healthy volunteers, as determined by medical evaluation including medical history, physical examination, and laboratory testing.
  3. No diagnosis of AUD within the preceding 12 months per (DSM-5).
  4. Social drinkers who consume, on average, 5 to 20 drinks per week for men or 5 to 14 drinks per week for women over the 4 weeks prior to Screening, and not more than 8 drinks in a single day.
  5. No evidence of overt or sub-clinical hepatic pathology, as manifest by serologic tests demonstrating hepatic inflammation or compromised hepatic synthetic function (i.e., , ALT, GGT, total \< 1.5 times the at Screening and Day -1).
  6. ≥ 60 mL/min/1.73 m2 at Screening.
  7. No history of significant adverse reaction(s) to alcohol. Participant should be expected to tolerate the amount of alcohol administered during EIAs.
  8. Willing to participate in up to 10 EIAs.
  9. Has a negative test for SARS-CoV-2 infection on Day -1.
  10. Systolic BP in the range of 80 to 140 mmHg and diastolic BP in the range of 50 to 95 mmHg at Screening. If out of range, BP may be repeated once at the discretion of the Investigator.
  11. Male or female

    • Male participants with partners of must agree to use from Screening through at least 24 weeks after the last dose of study intervention and refrain from donating sperm during this period (see Section 10.4).
    • Female participants may not be pregnant or breastfeeding, and at least one of the following conditions must apply:

      • Is not a woman of childbearing potential (WOCBP) or
      • If a WOCBP, must agree to follow the contraceptive guidance (see Section 10.4), beginning at consent and the first Screening visit and for at least 24 weeks after the last dose of study intervention.
  12. within the range 18.0 to 32.0 kg/m2 (inclusive).
  13. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

History of any medical condition that may interfere with the metabolism of study intervention or with the clinical and laboratory assessments in this study. 2. History of serious, persistent medical conditions, including liver, gastrointestinal, pulmonary, renal, or cardiovascular abnormalities. 3. History of suicidal attempt at any time or an answer of "yes" on any of the following items in the C-SSRS at Screening:

  1. Items 1 or 2 of the Suicidal Ideation section, if ideation occurred in the previous 12 months.
  2. Items 4 or 5 of the Suicidal Ideation section, in lifetime.
  3. Any item of the Suicidal Behavior section of the C-SSRS, in lifetime. 4. Any history of severe or recent depression, anxiety, bipolar disorder, schizophrenia, or other neuropsychiatric disorder that, in the judgement of the Investigator, represents a safety risk to the participant were they to participate in the trial, as informed by the participant's medical history and/or responses to the MINI Screen Questionnaire. 5. History of substance use disorder (SUD) or illicit drug use (excluding cannabis) within the preceding 12 months. 6. History of alcohol withdrawal symptoms including delirium tremens or alcohol-related seizures. 7. Any condition that, in the opinion of the Investigator, would make the participant unsuitable for participation or could interfere with participation in or completion of the study, including:

a. Poorly controlled or unstable hypertension. b. Diabetes mellitus treated with insulin or hypoglycemic agents (including metformin) or > 7%. Asthma requiring hospital admission within the preceding 12 months. NOTE: Persons with clinically stable asthma who have not been hospitalized in the prior year and are treated only with orally inhaled medications are not excluded. d. Currently poorly controlled endocrine conditions, except for hypothyroidism that is stable (no treatment change in prior 6 months). e. Significant infection or known systemic inflammatory process ongoing at Screening.

f. History of chronic or recurrent UTI, or UTI within 1 month prior to Screening.

8. History of within the preceding 5 years requiring treatment, with the exception of excised low grade basal cell skin neoplasms. 9. History of any concomitant medical condition for which alcohol consumption is prohibited or advised against by the participant's physician or health care provider.

10. SARS-CoV-2 infection in the 14 days prior to randomization. 11. Clinically significant illness within the 7 days prior to the first administration of study intervention. History of multiple drug allergies or a history of allergic reaction to an oligonucleotide based therapy.

13. Use of prescription medications (except for hormonal replacement/ medication for women and inhaled medication for treatment of clinically stable asthma) within 14 days or 5 half-lives (whichever is longer) prior to administration of study intervention. Participants being treated for hypothyroid disease must be on stable treatment (no treatment changes in the preceding 6 months). 14. Receipt of any vaccine (including COVID-19) within 14 days prior to the first administration of study intervention. 15. Regular use of OTC medications, including NSAID (periodic or occasional NSAID use to control temporary pain is not exclusionary). 16. Previously participated in Dicerna Study DCR-AUD-101. 17. Has received an agent within 30 days or 5 half-lives (whichever is longer) prior to dosing or is in follow-up of another clinical study prior to initial dosing with the study intervention. 18. Clinically significant abnormalities in vital signs at Screening: pulse rate (\< 40 bpm or > 90 bpm), respiratory rate, or temperature. 19. Clinically significant abnormalities in 12-lead at Screening or predose on Day 1, including > 470 msec in females and > 450 msec in males. 20. Positive urine drug test at Screening or Day -1. Tests positive for cannabis are not exclusionary. 21. Seropositive for antibodies to , , or at Screening (historical testing may be used if performed within the 3 months prior to screening). NOTE: In participants with previous treatment for hepatitis C with direct-acting HCV medication and seropositivity for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA must be undetectable (at least 2 negative HCV RNA tests at least 12 weeks apart), and the HCV infection must have been resolved or cured > 3 years prior to initial dosing with the investigational medication. 22. Safety laboratory test result at Screening considered clinically unacceptable for study participation by the Investigator. 23. History of intolerance to SC injection(s) or significant abdominal scarring that could potentially hinder study intervention administration or evaluation of local injection site tolerability. 24. Scheduled for an elective surgical procedure during the conduct of this study.

25. Donation of > 500 mL of blood within the 2 months prior to administration of study intervention or donation of plasma within 7 days prior to Screening.

Life Style Considerations:

  1. Study participants are to refrain from drinking alcohol for 24 hours prior to each EIA and must have a negative breath-alcohol test on the day of the study visit.
  2. Study participants will be advised to avoid consuming more than 4 drinks during any drinking session outside of in-clinic EIAs.
  3. Study participants will be instructed to stop drinking at the onset of any ethanol reaction symptoms during outside drinking sessions.
  4. Tobacco/nicotine use is not restricted.
  5. Study participants are to refrain from using cannabis for 24 hours prior to each EIA and must have a negative urine-drug test on the day of the study visit.
  6. Study participants should abstain from strenuous exercise for 24 hours before each blood collection for clinical laboratory tests. Participants may participate in light recreational activities (e.g., walking at a pace \< 3 miles per hour, shopping, watering plants) in that 24-hour time period.
  7. For each EIA study visit, participants will be required to fast for at least 3 hours and then will be fed a standardized meal in the clinic prior to administration of ETOH for the EIA.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    DCR-AUD

    Multiple doses of DCR-AUD. Subcutaneous administration of of DCR-AUD.

    Drug: DCR-AUD

  • Placebo comparator
    DCR-AUD Placebo

    Multiple doses of placebo comparator. Subcutaneous administration of Placebo for DCR-AUD, volume to match active single dose

    Drug: Placebo

Interventions

  • DrugDCR-AUD

    DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

    Also known as: DCR-A1203

  • DrugPlacebo

    0.9% saline for injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as an AE that begins or that worsens in severity after the study drug has been administered. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.

    Time frame: From Day 1 up to 24 Weeks

  2. Number of Participants With Severity Grades of TEAEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE that begins or that worsens in severity after the study drug has been administered. As per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately lifethreatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

    Time frame: From Day 1 up to 24 Weeks

  3. Number of Participants With Change From Baseline in Clinically Significant Abnormal Vital Signs

    Number of participants with change from baseline in clinically significant abnormal vital signs (temperature, pulse rate, respiratory rate, and blood pressure) is presented.

    Time frame: From Baseline (Day -1) up to 24 weeks

  4. Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

    Number of participants with change from baseline in clinically significant abnormal ECG findings (Heart rate, PR interval, QRS interval, QT interval and QT interval using Fridericia's correction \[QTcF\]) is presented.

    Time frame: From Baseline (Day -1) up to 24 weeks

  5. Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

    Number of participants with change from baseline in clinically significant abnormal laboratory values (hematology, clinical chemistry, coagulation and routine urinalysis parameters) is presented.

    Time frame: From Baseline (Day -1) up to 24 weeks

  6. Number of Participants With Change From Baseline in Clinically Significant Physical Examination Findings

    Number of participants with change from baseline in clinically significant physical examination findings (assessments of the cardiovascular, respiratory, gastrointestinal, neurological, and skin systems and inspection of the injection site) is presented.

    Time frame: From Baseline (Day -1) up to 24 weeks

Secondary outcomes

  1. Six Symptom Responses During Ethanol Interactions Assessments (EIAs)

    The degree of aldehyde dehydrogenase 2 (ALDH2) reduction was measured by quantitative assessment of 6 symptom (flushing, headache, palpitations, light-headedness, nausea, and vomiting) responses during EIAs. Each of 6 symptoms was assessed at each of the 4 time points during each EIA. Composite score at each time point was the sum of severity ratings for each of the 6 symptoms. Peak composite score (of the 3 post-alcohol initiation composite scores at each EIA test) was used as the subject's peak score for that EIA test. The point system was as follows: 0 point = symptom not present, 1 point = mild severity of symptom, 2 points = moderate severity of symptom and 3 points = severe severity of symptom. Participants were given a composite score, which was the sum of the scores of all 6 symptoms (highest possible score is 18).

    Time frame: Day -1 (baseline), Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168

  2. AUC0-last: Area Under the Plasma Concentration Curve From Time Zero to the Last Quantifiable Concentration of DCR-AUD

    AUC0-last is defined as the area under the plasma concentration curve from time zero to the last quantifiable concentration of DCR-AUD.

    Time frame: Day 1, Day 29 and Day 57

  3. Cmax: Maximum Observed Plasma Concentration of DCR-AUD

    Cmax is defined as maximum observed plasma concentration of DCR-AUD is presented.

    Time frame: Day 1, Day 29 and Day 57

  4. Tmax: Time to Reach the Maximum Plasma Concentration of DCR-AUD (Cmax)

    Tmax is defined as time to reach the maximum plasma concentration (Cmax) of DCR-AUD.

    Time frame: Day 1, Day 29 and Day 57

  5. Cmax: Maximum Observed Plasma Concentration of Acetaldehyde

    Maximum observed plasma concentration of acetaldehyde levels was measured to evaluate the pharmacodynamic effects of ALDH2 reduction by DCR-AUD during serial EIAs.

    Time frame: Day -1 (baseline), Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168

  6. AUC0-4: Area Under the Concentration Time Curve From Time 0 to Fixed Time 4 of Acetaldehyde

    Area under the concentration time curve from time 0 to fixed time 4 of acetaldehyde levels was measured to evaluate the pharmacodynamic effects of ALDH2 reduction by DCR-AUD during serial EIAs.

    Time frame: Day -1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168

  7. Change From Baseline in Heart Rate

    Heart rate is measured to evaluate the PD effects of ALDH2 reduction by DCR-AUD during serial EIA. Heart rate was monitored by telemetry during the EIAs.

    Time frame: Baseline, Day 169

  8. Change From Baseline in Facial Skin Temperature

    Change in facial skin temperature was measured to evaluate the PD effects of ALDH2 reduction by DCR-AUD during serial EIAs.

    Time frame: Baseline, Day 169

07

Results

Posted Jan 3, 2025

Participant flow

The study was conducted at 1 site in the United States of America.

Participant flow — Overall Study
MilestoneDCR-AUDPlacebo
Started124
Pharmacokinetic population120
Pharmacodynamic population124
Completed124
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as an AE that begins or that worsens in severity after the study drug has been administered. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.

Time frame:
From Day 1 up to 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsDCR-AUDPlacebo
TEAEs113
SAEs00
PrimaryNumber of Participants With Severity Grades of TEAEs

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE that begins or that worsens in severity after the study drug has been administered. As per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately lifethreatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.

Time frame:
From Day 1 up to 24 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Severity Grades of TEAEs
ParticipantsDCR-AUDPlacebo
Grade 1113
Grade 230
Grade 300
Grade 400
Grade 500
PrimaryNumber of Participants With Change From Baseline in Clinically Significant Abnormal Vital Signs

Number of participants with change from baseline in clinically significant abnormal vital signs (temperature, pulse rate, respiratory rate, and blood pressure) is presented.

Time frame:
From Baseline (Day -1) up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinically Significant Abnormal Vital Signs
ParticipantsDCR-AUDPlacebo
Number of Participants With Change From Baseline in Clinically Significant Abnormal Vital Signs00
PrimaryNumber of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)

Number of participants with change from baseline in clinically significant abnormal ECG findings (Heart rate, PR interval, QRS interval, QT interval and QT interval using Fridericia's correction \[QTcF\]) is presented.

Time frame:
From Baseline (Day -1) up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
ParticipantsDCR-AUDPlacebo
Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)00
PrimaryNumber of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values

Number of participants with change from baseline in clinically significant abnormal laboratory values (hematology, clinical chemistry, coagulation and routine urinalysis parameters) is presented.

Time frame:
From Baseline (Day -1) up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
ParticipantsDCR-AUDPlacebo
Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values00
PrimaryNumber of Participants With Change From Baseline in Clinically Significant Physical Examination Findings

Number of participants with change from baseline in clinically significant physical examination findings (assessments of the cardiovascular, respiratory, gastrointestinal, neurological, and skin systems and inspection of the injection site) is presented.

Time frame:
From Baseline (Day -1) up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinically Significant Physical Examination Findings
ParticipantsDCR-AUDPlacebo
Number of Participants With Change From Baseline in Clinically Significant Physical Examination Findings00
SecondarySix Symptom Responses During Ethanol Interactions Assessments (EIAs)

The degree of aldehyde dehydrogenase 2 (ALDH2) reduction was measured by quantitative assessment of 6 symptom (flushing, headache, palpitations, light-headedness, nausea, and vomiting) responses during EIAs. Each of 6 symptoms was assessed at each of the 4 time points during each EIA. Composite score at each time point was the sum of severity ratings for each of the 6 symptoms. Peak composite score (of the 3 post-alcohol initiation composite scores at each EIA test) was used as the subject's peak score for that EIA test. The point system was as follows: 0 point = symptom not present, 1 point = mild severity of symptom, 2 points = moderate severity of symptom and 3 points = severe severity of symptom. Participants were given a composite score, which was the sum of the scores of all 6 symptoms (highest possible score is 18).

Time frame:
Day -1 (baseline), Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168
Reported as:
Mean · Score on a scale
Six Symptom Responses During Ethanol Interactions Assessments (EIAs)
Score on a scaleDCR-AUDPlacebo
Day -1 (baseline)0.3 ± 0.650.5 ± 0.58
Day 140.4 ± 0.670 ± 0
Day 280.8 ± 0.750.5 ± 0.58
Day 420.9 ± 1.080.8 ± 0.96
Day 561.1 ± 1.140.3 ± 0.50
Day 701.0 ± 1.210 ± 0
Day 841.1 ± 1.240 ± 0
Day 1120.9 ± 1.220 ± 0
Day 1400.8 ± 1.060.3 ± 0.50
Day 1680.8 ± 0.870.3 ± 0.50
SecondaryAUC0-last: Area Under the Plasma Concentration Curve From Time Zero to the Last Quantifiable Concentration of DCR-AUD

AUC0-last is defined as the area under the plasma concentration curve from time zero to the last quantifiable concentration of DCR-AUD.

Time frame:
Day 1, Day 29 and Day 57
Reported as:
Geometric mean · hour*nanogram per millilitre (h*ng/ mL)
AUC0-last: Area Under the Plasma Concentration Curve From Time Zero to the Last Quantifiable Concentration of DCR-AUD
hour*nanogram per millilitre (h*ng/ mL)DCR-AUD
Day 144100 ± 16.3
Day 2941000 ± 16.9
Day 5766200 ± 27.0
SecondaryCmax: Maximum Observed Plasma Concentration of DCR-AUD

Cmax is defined as maximum observed plasma concentration of DCR-AUD is presented.

Time frame:
Day 1, Day 29 and Day 57
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Cmax: Maximum Observed Plasma Concentration of DCR-AUD
nanogram per millilitre (ng/mL)DCR-AUD
Day 12530 ± 28.1
Day 292280 ± 32.3
Day 571900 ± 26.3
SecondaryTmax: Time to Reach the Maximum Plasma Concentration of DCR-AUD (Cmax)

Tmax is defined as time to reach the maximum plasma concentration (Cmax) of DCR-AUD.

Time frame:
Day 1, Day 29 and Day 57
Reported as:
Median · Hours
Tmax: Time to Reach the Maximum Plasma Concentration of DCR-AUD (Cmax)
HoursDCR-AUD
Day 14.95 (1.00 to 8.01)
Day 294.99 (1.02 to 8.00)
Day 573.98 (1.00 to 8.10)
SecondaryCmax: Maximum Observed Plasma Concentration of Acetaldehyde

Maximum observed plasma concentration of acetaldehyde levels was measured to evaluate the pharmacodynamic effects of ALDH2 reduction by DCR-AUD during serial EIAs.

Time frame:
Day -1 (baseline), Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168
Reported as:
Mean · Micromolar (μM)
Cmax: Maximum Observed Plasma Concentration of Acetaldehyde
Micromolar (μM)DCR-AUDPlacebo
Day -1 (baseline)19.8 ± 5.7128.3 ± 17.1
Day 1421.6 ± 14.124.3 ± 3.51
Day 2840.2 ± 27.915.1 ± 6.88
Day 4234.0 ± 19.912.6 ± 3.51
Day 5653.9 ± 29.626.7 ± 14.9
Day 7058.6 ± 46.336.3 ± 23.8
Day 8462.9 ± 23.020.7 ± 13.8
Day 11280.3 ± 37.825.3 ± 21.7
Day 14098.3 ± 40.721.9 ± 16.2
Day 168132 ± 48.630.6 ± 24.1
SecondaryAUC0-4: Area Under the Concentration Time Curve From Time 0 to Fixed Time 4 of Acetaldehyde

Area under the concentration time curve from time 0 to fixed time 4 of acetaldehyde levels was measured to evaluate the pharmacodynamic effects of ALDH2 reduction by DCR-AUD during serial EIAs.

Time frame:
Day -1, Day 14, Day 28, Day 42, Day 56, Day 70, Day 84, Day 112, Day 140 and Day 168
Reported as:
Mean · Micromolar*hours (μM*h)
AUC0-4: Area Under the Concentration Time Curve From Time 0 to Fixed Time 4 of Acetaldehyde
Micromolar*hours (μM*h)DCR-AUDPlacebo
Day -147.8 ± 20.365.8 ± 48.0
Day 1448.2 ± 43.162.1 ± 11.6
Day 2893.2 ± 68.632.0 ± 24.6
Day 4281.8 ± 52.921.6 ± 10.7
Day 56131 ± 81.854.4 ± 48.9
Day 70135 ± 88.978.3 ± 51.2
Day 84135 ± 52.449.5 ± 45.6
Day 112187 ± 75.957.5 ± 63.6
Day 140228 ± 85.156.8 ± 63.5
Day 168334 ± 93.969.4 ± 70.0
SecondaryChange From Baseline in Heart Rate

Heart rate is measured to evaluate the PD effects of ALDH2 reduction by DCR-AUD during serial EIA. Heart rate was monitored by telemetry during the EIAs.

Time frame:
Baseline, Day 169
Reported as:
Mean · beats per minute (beats/min)
Change From Baseline in Heart Rate
beats per minute (beats/min)DCR-AUDPlacebo
Change From Baseline in Heart Rate1.9 ± 9.094.3 ± 8.10
SecondaryChange From Baseline in Facial Skin Temperature

Change in facial skin temperature was measured to evaluate the PD effects of ALDH2 reduction by DCR-AUD during serial EIAs.

Time frame:
Baseline, Day 169
Reported as:
Mean · degree celsius
Change From Baseline in Facial Skin Temperature
degree celsiusDCR-AUDPlacebo
Change From Baseline in Facial Skin Temperature-0.05 ± 0.5550.03 ± 0.704

Adverse events

Collected over From Day 1 until end of the study (24 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DCR-AUD0/12 (0%)0/12 (0%)11/12 (91.7%)
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventDCR-AUDPlacebo
HeadacheNervous system disorders6/120/4
FlushingVascular disorders5/120/4
DizzinessNervous system disorders3/120/4
Hot flushVascular disorders3/121/4
NauseaGastrointestinal disorders3/121/4
DiarrhoeaGastrointestinal disorders1/121/4
Abdominal pain upperGastrointestinal disorders0/121/4
PalpitationsCardiac disorders3/120/4
Back painMusculoskeletal and connective tissue disorders1/121/4
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/121/4

Baseline characteristics

Safety Population (SP): All participants randomized to study intervention and who receive at least 1 dose of DCR-AUD or placebo.

Age, Continuous
Age, Continuous(Years)DCR-AUDPlaceboTotal
Mean39.3 ± 9.9138.0 ± 3.3739.0 ± 8.64
Sex: Female, Male
Sex: Female, Male(Participants)DCR-AUDPlaceboTotal
Female9110
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DCR-AUDPlaceboTotal
Hispanic or Latino516
Not Hispanic or Latino7310
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DCR-AUDPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American325
White9211
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Parexel Los Angeles Early Phase Clinical Unit
    Glendale, California 91206, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Aug 2023, 6 months.

Results were first posted in Jan 2025, 1 year 4 months after primary completion.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
Jan 29, 2023
Primary completionActual
Aug 22, 2023
CompletionActual
Aug 22, 2023
Results first posted
Jan 3, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05845398
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jan 29, 2023
Primary completion
Aug 22, 2023
Completion
Aug 22, 2023
Results posted
Jan 3, 2025
Last update
Jan 14, 2026

Study contacts

John Hanrahan, MD, MPH
study director · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Lev G. Gertsik, MD
principal investigator · Parexel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion